iPS Cell-based Parkinson’s Drug Face Challenges Over High Cost, Unverified Efficacy After Receiving Temporary Approval

The decision to make an iPS-derived medicine for Parkinson’s disease available under public health insurance marks a major step forward for treatment. However, it remains necessary to verify its efficacy and whether it is worth its high price tag.

Go to News Site